Okay, we exaggerate but have you seen the size of some supplement tablets? Or you often end up with a wet face when applying eye drops because you can't help but blink. It’s a tale as old as the need ...

Rationale The most common antibiotic used to treat people with cystic fibrosis (PWCF) is inhaled tobramycin, administered as maintenance therapy for chronic Pseudomonas aeruginosa lung infections.

Have you ever wondered if VR is bad for your eyes? Here's what experts have to say about virtual reality headsets. Jessica was a writer on the Wellness team, with a focus on health technology, eye ...

The equity benchmarks maintained their upward momentum in Thursday afternoon trading, with both the Sensex and Nifty posting gains amid mixed global cues following the US Federal Reserve’s rate ...

Cipla Q3 results review: The shares of the third largest pharmaceutical firm Cipla rose 2.44 per cent at Rs 1,454.20 a piece on the BSE intraday after the company delivered a solid quarterly earnings ...

Shares of drugmaker Cipla Ltd. surged to the day's high, gaining as much as 4% after the company's December quarter results. The results were a beat across parameters.

Cipla Ltd. has expressed optimism about exceeding its FY25 guidance, supported by strong operational performance and a focused strategy. The company stated that supply challenges related to Lanreotide ...

HYDERABAD/BENGALURU (Reuters) -Cipla, one of India's largest drugmakers by sales, reported a bigger-than-expected third-quarter profit on Tuesday helped by strong domestic demand, and said the U.S ...

Drug major Cipla on Tuesday reported a 49% jump in its December quarter consolidated net profit at Rs 1,571 crore as compared to Rs 1,056 crore reported in the year-ago period. The profit after tax ...

Cipla Ltd.'s consolidated net profit rose 49% year-on-year in the third quarter of the current financial year, beating analysts' estimates by a substantial margin. The drugmaker posted a consolidated ...

After topping the Street's expectations with its Q3 earnings, Cipla announced plans to launch two key drugs in FY26—the respiratory drug Advair and the oncology drug Abraxane. Umang Vohra ...

Pharmaceutical giant Cipla on January 28 reported a consolidated net profit of Rs 1,571 crore for the quarter ended on December 31. This marks a 49 percent rise from the Rs 1,056 crore net profit ...